4.5 Review

Understanding protein-drug interactions using ion mobility-mass spectrometry

Journal

CURRENT OPINION IN CHEMICAL BIOLOGY
Volume 42, Issue -, Pages 167-176

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2017.12.013

Keywords

-

Funding

  1. Biotechnology and Biological Sciences Research Council (BBSRC) [BB/L009501/1, BB/M012557/1, BB/R000182/1]
  2. Biotechnology and Biological Sciences Research Council (BBSRC) (BBSRC DTP studentship)
  3. North West Cancer Research [CR1037, CR1088]
  4. Institute of Integrative Biology, University of Liverpool
  5. BBSRC [BB/R000182/1, BB/L009501/1, BB/M012557/1] Funding Source: UKRI
  6. Biotechnology and Biological Sciences Research Council [BB/L009501/1, BB/M012557/1, BB/R000182/1] Funding Source: researchfish

Ask authors/readers for more resources

Ion mobility-mass spectrometry (IM-MS) is an important addition to the analytical toolbox for the structural evaluation of proteins, and is enhancing many areas of biophysical analysis. Disease-associated proteins, including enzymes such as protein kinases, transcription factors exemplified by p53, and intrinsically disordered proteins, including those prone to aggregation, are all amenable to structural analysis by IM-MS. In this review we discuss how this powerful technique can be used to understand protein conformational dynamics and aggregation pathways, and in particular, the effect that small molecules, including clinically-relevant drugs, play in these processes. We also present examples of how IM-MS can be used as a relatively rapid screening strategy to evaluate the mechanisms and conformation-driven aspects of protein:ligand interactions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available